Literature DB >> 31391734

Can Polycystic Ovarian Syndrome be cured? Unfolding the Concept of Secondary Polycystic Ovarian Syndrome!

Suvarna Satish Khadilkar1.   

Abstract

Classic polycystic ovarian syndrome (PCOS) is one of the commonest endocrine metabolic disorders in women of reproductive years. It is very disappointing that we have still not been able to know the exact cause, and hence, we cannot completely cure this syndrome. With availability of effective drugs and lifestyle modification, it can only be controlled and symptoms can be reduced. There are some well-defined factors which lead to PCOS phenotype. A concept of secondary PCOS is being described recently. This condition, even though rare, is completely curable, as majority of these factors are treatable. Hence, it is advisable to actively look for these conditions and offer treatment in time. This editorial gives an account of various causes of secondary PCOS, gives broader view of PCOS phenotypes and aims for an insight into pathophysiological aspects of PCOS. The clinical categorization by HA-PODS nomenclature of both primary and secondary PCOS can minimize diagnostic and therapeutic pitfalls and will serve as a checklist to ensure the appropriate investigation is ordered and specific treatment is initiated as per diagnostic code. This will achieve uniformity in therapies offered and also enable better comparison of data and a smooth conduct of research which is much needed in this field.

Entities:  

Keywords:  Autoimmune thyroiditis; Congenital adrenal hyperplasia; HA-PODS; Hyperandrogenaemia; Hyperprolactinaemia; Hypothyroidism; Insulin resistance; Menstrual dysfunction; Obesity; Polycystic ovarian syndrome; Secondary PCOS

Year:  2019        PMID: 31391734      PMCID: PMC6661052          DOI: 10.1007/s13224-019-01253-z

Source DB:  PubMed          Journal:  J Obstet Gynaecol India        ISSN: 0975-6434


  26 in total

1.  Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation.

Authors:  P Moghetti; R Castello; C Negri; F Tosi; F Perrone; M Caputo; E Zanolin; M Muggeo
Journal:  J Clin Endocrinol Metab       Date:  2000-01       Impact factor: 5.958

2.  Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature.

Authors:  Ricardo Azziz
Journal:  J Clin Endocrinol Metab       Date:  2006-01-17       Impact factor: 5.958

3.  The polycystic ovary syndrome associated with morbid obesity may resolve after weight loss induced by bariatric surgery.

Authors:  Héctor F Escobar-Morreale; José I Botella-Carretero; Francisco Alvarez-Blasco; José Sancho; José L San Millán
Journal:  J Clin Endocrinol Metab       Date:  2005-09-27       Impact factor: 5.958

Review 4.  Menstrual disorders in women with epilepsy.

Authors:  Andrew G Herzog
Journal:  Neurology       Date:  2006-03-28       Impact factor: 9.910

5.  Polycystic ovarian syndrome: marked differences between endocrinologists and gynaecologists in diagnosis and management.

Authors:  Andrea J Cussons; Bronwyn G A Stuckey; John P Walsh; Valerie Burke; Robert J Norman
Journal:  Clin Endocrinol (Oxf)       Date:  2005-03       Impact factor: 3.478

6.  Androgen suppression and clinical improvement with dopamine agonists in hyperandrogenic-hyperprolactinemic women.

Authors:  P Hagag; I Hertzianu; A Ben-Shlomo; M Weiss
Journal:  J Reprod Med       Date:  2001-07       Impact factor: 0.142

Review 7.  Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS).

Authors: 
Journal:  Hum Reprod       Date:  2004-01       Impact factor: 6.918

8.  Valproate potentiates androgen biosynthesis in human ovarian theca cells.

Authors:  Velen L Nelson-DeGrave; Jessica K Wickenheisser; Jennifer E Cockrell; Jennifer R Wood; Richard S Legro; Jerome F Strauss; Jan M McAllister
Journal:  Endocrinology       Date:  2003-10-23       Impact factor: 4.736

9.  Androgen excess in women: experience with over 1000 consecutive patients.

Authors:  R Azziz; L A Sanchez; E S Knochenhauer; C Moran; J Lazenby; K C Stephens; K Taylor; L R Boots
Journal:  J Clin Endocrinol Metab       Date:  2004-02       Impact factor: 5.958

10.  Monogenic polycystic ovary syndrome due to a mutation in the lamin A/C gene is sensitive to thiazolidinediones but not to metformin.

Authors:  A Gambineri; R K Semple; G Forlani; S Genghini; I Grassi; C S S Hyden; U Pagotto; S O'Rahilly; R Pasquali
Journal:  Eur J Endocrinol       Date:  2008-09       Impact factor: 6.664

View more
  1 in total

Review 1.  Beneficial Effects of Green Tea Catechins on Female Reproductive Disorders: A Review.

Authors:  Datu Agasi Mohd Kamal; Norizam Salamt; Siti Sarah Mohamad Zaid; Mohd Helmy Mokhtar
Journal:  Molecules       Date:  2021-05-03       Impact factor: 4.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.